报告期 | 销售毛利率 | 同比 | 环比 | 行业排名 | 行业均值 | 行业龙头股 | 龙头股该指标值 | 查看 |
---|---|---|---|---|---|---|---|---|
2024-09-30 | 33.2% | 0.49% | -4.67% | 114/160 | 22.89% | 迪哲医药 | 97.73% | 行业排名> |
2024-06-30 | 34.83% | -1.16% | 0.97% | 111/160 | 33.26% | 百利天恒 | 97.99% | 行业排名> |
2024-03-31 | 34.49% | -1.15% | 4.34% | 109/160 | 51.37% | 百利天恒 | 98.92% | 行业排名> |
2023-12-31 | 33.06% | 1.39% | 0.06% | 113/160 | 51.37% | 迈威生物 | 98.93% | 行业排名> |
2023-09-30 | 33.04% | 2.41% | -6.24% | 113/160 | 32.75% | 迈威生物 | 99.59% | 行业排名> |
2023-06-30 | 35.24% | 8.18% | 0.98% | 112/160 | 38.61% | 迈威生物 | 99.8% | 行业排名> |
2023-03-31 | 34.9% | 15.11% | 7.03% | 111/160 | 52.91% | 迈威生物 | 99.46% | 行业排名> |
2022-12-31 | 32.61% | 2.09% | 1.06% | 117/160 | 53.57% | 迈威生物 | 99.75% | 行业排名> |
2022-09-30 | 32.26% | 2.58% | -0.96% | 110/160 | 6.69% | 迈威生物 | 99.67% | 行业排名> |
2022-06-30 | 32.58% | 3.28% | 7.45% | 116/160 | 21.79% | 迈威生物 | 99.44% | 行业排名> |
2022-03-31 | 30.32% | -8.04% | -5.08% | 112/160 | 54.47% | 迈威生物 | 98.57% | 行业排名> |
2021-12-31 | 31.94% | -18.43% | 1.55% | 125/160 | 55.07% | 首药控股 | 99.93% | 行业排名> |
2021-09-30 | 31.45% | -19.95% | -0.29% | 108/160 | 47.01% | 艾力斯 | 99.41% | 行业排名> |
2021-06-30 | 31.54% | -25.11% | -4.32% | 120/160 | 47.45% | 艾力斯 | 98.7% | 行业排名> |
2021-03-31 | 32.97% | -24.85% | -15.81% | 101/160 | 54.21% | 艾力斯 | 99.4% | 行业排名> |
2020-12-31 | 39.16% | 4.95% | -0.34% | 110/160 | -143.08% | 首药控股 | 99.94% | 行业排名> |
2020-09-30 | 39.29% | 10.97% | -6.72% | 92/160 | 56.57% | 泽璟制药 | 99.96% | 行业排名> |
2020-06-30 | 42.12% | 21.01% | -3.99% | 91/160 | 54.32% | 微芯生物 | 95.14% | 行业排名> |
2020-03-31 | 43.87% | 22.34% | 17.58% | 77/160 | 55.5% | 多瑞医药 | 95.59% | 行业排名> |
2019-12-31 | 37.31% | -6.56% | 5.38% | 106/160 | -1204.25% | 微芯生物 | 95.81% | 行业排名> |
2019-09-30 | 35.4% | -10.11% | 1.72% | 88/160 | 55.47% | 微芯生物 | 96.09% | 行业排名> |
2019-06-30 | 34.8% | -11.19% | -2.94% | 95/160 | 55.36% | 微芯生物 | 96.11% | 行业排名> |
2019-03-31 | 35.86% | -12.48% | -10.2% | 85/160 | 51.37% | 微芯生物 | 95.5% | 行业排名> |
2018-12-31 | 39.93% | 26.03% | 1.39% | 97/160 | -205.91% | 微芯生物 | 96.27% | 行业排名> |
2018-09-30 | 39.38% | 32.54% | 0.5% | 73/160 | 54.25% | 贝达药业 | 95.47% | 行业排名> |
2018-06-30 | 39.19% | 55% | -4.35% | 75/160 | 53.68% | 贝达药业 | 95.51% | 行业排名> |
2018-03-31 | 40.97% | 68.02% | 29.32% | 70/160 | 54.19% | 贝达药业 | 95.54% | 行业排名> |
2017-12-31 | 31.68% | -0.97% | 6.63% | 96/160 | 52.58% | 贝达药业 | 95.74% | 行业排名> |
2017-09-30 | 29.71% | -6.03% | 17.53% | 79/160 | 49.32% | 退市金泰 | 96.19% | 行业排名> |
2017-06-30 | 25.28% | -25.63% | 3.68% | 92/160 | 48.02% | 贝达药业 | 95.81% | 行业排名> |
2017-03-31 | 24.39% | -33.86% | -23.78% | 79/160 | 46.89% | 退市金泰 | 95.93% | 行业排名> |
2016-12-31 | 31.99% | -13.59% | 1.17% | 87/160 | 48.44% | 贝达药业 | 95.58% | 行业排名> |
2016-09-30 | 31.62% | -11.47% | -6.98% | 58/160 | 45.76% | 贝达药业 | 95.89% | 行业排名> |
2016-06-30 | 34% | -4.68% | -7.8% | 65/160 | 46.2% | 微芯生物 | 97.46% | 行业排名> |
2016-03-31 | 36.87% | 1.85% | -0.42% | 46/160 | 43.5% | 贝达药业 | 97.01% | 行业排名> |
2015-12-31 | 37.03% | 28.28% | 3.66% | 65/160 | 46.24% | 贝达药业 | 97.02% | 行业排名> |
2015-09-30 | 35.72% | 23.7% | 0.15% | 48/160 | 44.69% | 舒泰神 | 94.38% | 行业排名> |
2015-06-30 | 35.67% | 49% | -1.48% | 54/160 | 45.36% | 贝达药业 | 96.95% | 行业排名> |
2015-03-31 | 36.2% | 90.18% | 25.42% | 45/160 | 43.46% | 舒泰神 | 94.4% | 行业排名> |